1[4]SUKHOVA GK, SCHONBECK U, RABKIN E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheramatous plaques[J]. Circulation, 1999, 99(19):2503-2509.
2[5]SHI GP, SUKHOVA GK, GRUBB A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms[J]. J Clin Invest, 1999, 104(9):1191-1197.
3[6]MACH F, SCHONBECK U, FABUNMI RP, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation[J]. Am J Pathol, 1999, 154(1):229-238.
5[8]BUSTOS C, HERNANDEZ-PRESA MA, ORTEGO M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis[J]. J Am Coll Cardiol, 1998, 32(7):2057-2064.
6[9]RIDKER PM, RIFAI N, PFEFFER MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators[J]. Circulation, 1999, 100(3):230-235.
7[10]AIKAWA M, VOGLIC SJ, SUGIYAMA S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma[J]. Circulation, 1999, 100(11):1215-1222.
8[11]MOULTON KS, HELLER E, KONERDING MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice[J]. Circulation, 1999, 99(13):1726-1732.
9[12]ENDRES M, LAUFS U, HUANG Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl(HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase[J]. Proc Natl Acad Sci USA, 1998, 95(15):8880-8885.
10[13]LIBBY P. Current concepts of the pathogenesis of the acute coronary syndromes[J]. Circulation, 2001, 104(3):365-372.
